BioDuro-Sundia Acquires US-based Phase III/Commercial Drug Product Manufacturing Facility

SAN DIEGO–(BUSINESS WIRE)–BioDuro-Sundia, a leading drug discovery and development services organization backed by Advent International, announced today it has entered into a definitive agreement to acquire a 40,000 ft2 commercial oral solid dose manufacturing facility located at 72 Fairbanks, Irvine, CA, USA. Subject to customary closing conditions, BioDuro-Sundia expects to begin commercial service operations at the site on January 1, 2022. “This fully-audited and operational facility allow
Click here to view original post